Nisa Investment Advisors LLC Boosts Holdings in Insulet Co. (NASDAQ:PODD)

Nisa Investment Advisors LLC raised its holdings in shares of Insulet Co. (NASDAQ:PODD) by 195.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,098 shares of the medical instruments supplier’s stock after acquiring an additional 2,049 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Insulet were worth $672,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently added to or reduced their stakes in PODD. Parkside Financial Bank & Trust increased its holdings in Insulet by 251.0% during the 3rd quarter. Parkside Financial Bank & Trust now owns 172 shares of the medical instruments supplier’s stock valued at $27,000 after acquiring an additional 123 shares in the last quarter. Allworth Financial LP increased its holdings in Insulet by 104.5% during the 3rd quarter. Allworth Financial LP now owns 180 shares of the medical instruments supplier’s stock valued at $29,000 after acquiring an additional 92 shares in the last quarter. Wolff Wiese Magana LLC increased its holdings in Insulet by 2,680.0% during the 4th quarter. Wolff Wiese Magana LLC now owns 139 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 134 shares in the last quarter. BluePath Capital Management LLC purchased a new stake in shares of Insulet during the third quarter worth about $31,000. Finally, First Manhattan Co. purchased a new stake in shares of Insulet during the fourth quarter worth about $35,000.

Analysts Set New Price Targets

PODD has been the subject of a number of recent research reports. Barclays lowered their price target on shares of Insulet from $214.00 to $213.00 and set an “equal weight” rating for the company in a report on Monday, February 26th. JPMorgan Chase & Co. lifted their price target on shares of Insulet from $190.00 to $225.00 and gave the stock an “overweight” rating in a report on Friday, February 23rd. Stifel Nicolaus lifted their price target on shares of Insulet from $163.00 to $208.00 and gave the stock a “hold” rating in a report on Monday, February 5th. Robert W. Baird upgraded shares of Insulet from a “neutral” rating to an “outperform” rating and lifted their price target for the stock from $180.00 to $238.00 in a report on Thursday, December 21st. Finally, Piper Sandler lowered their price target on shares of Insulet from $250.00 to $230.00 and set an “overweight” rating for the company in a report on Friday, February 23rd. Four equities research analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $250.33.

Insulet Price Performance

PODD opened at $172.71 on Wednesday. The stock has a market capitalization of $12.09 billion, a PE ratio of 59.35, a P/E/G ratio of 3.15 and a beta of 0.98. The company has a debt-to-equity ratio of 1.86, a quick ratio of 2.62 and a current ratio of 3.51. Insulet Co. has a 1 year low of $125.82 and a 1 year high of $335.91. The company’s 50 day simple moving average is $175.79 and its 200 day simple moving average is $178.99.

Insulet (NASDAQ:PODD) last announced its quarterly earnings results on Thursday, February 22nd. The medical instruments supplier reported $1.40 earnings per share for the quarter, beating analysts’ consensus estimates of $0.67 by $0.73. The firm had revenue of $509.80 million for the quarter, compared to analysts’ expectations of $461.26 million. Insulet had a net margin of 12.16% and a return on equity of 32.19%. Insulet’s revenue was up 37.9% compared to the same quarter last year. During the same period in the previous year, the company posted $0.55 earnings per share. As a group, sell-side analysts expect that Insulet Co. will post 3.08 EPS for the current year.

Insider Buying and Selling at Insulet

In other Insulet news, Director Shacey Petrovic sold 11,609 shares of Insulet stock in a transaction that occurred on Wednesday, February 28th. The shares were sold at an average price of $162.92, for a total transaction of $1,891,338.28. Following the transaction, the director now directly owns 2,567 shares of the company’s stock, valued at $418,215.64. The sale was disclosed in a filing with the SEC, which is available at this link. 0.80% of the stock is currently owned by corporate insiders.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.